Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are... They are known to favour the development of masculine characteristics.
- Mechanism
- Curator reviewed
Bevirimat has a novel mechanism of action, specifically inhibiting cleavage of spacer peptide 1 (SP1) from the C-terminus of capsid which results in defective core condensation. Specifically, bevirimat binds at the SP1/capsid junction, preventing cleavage by HIV protease.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
- Formula / weight
- C36H56O6 · 584.8262 g/mol (avg)
- Code names
- MPC-4326 · PA-457 · YK-FH312
Resolves to
YJEJKUQEXFSVCJ-WRFMNRASSA-NSMILES[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=CWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Bevirimat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account